

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/511,465
Filing Date	October 14, 2004
First Named Inventor	Matthew H.T. Bui
Group Art Unit	Unassigned 1643
Examiner Name	Unassigned A.M. Harris, Ph.D.
Attorney Docket Number	306J-000220US
Date Submitted	March 29, 2005



## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
Amu	1	2002-0137910	A1	Zavada et al.	09-26-2002	
	2	2003-0049828	A1	Zavada et al.	03-13-2003	
	3	2004-0259126	A1	Zavada et al.	12-23-2004	
	4	2005-0003425	A1	Zavada et al.	01-06-2005	
	5	2005-0031623	A1	Pastorek et al.	02-10-2005	
	6	3,766,162		Hoffmann-La Roche, Inc	10-16-1973	
	7	3,791,932		Schuurs et al.	02-12-1974	
✓	8	3,817,837		Rubenstein et al.	06-18-1974	
	9	4,233,402		Maggio et al.	11-11-1980	
Amu	10	5,387,676		Zavada et al.	02-07-1995	
	11	5,955,075		Zavada et al.	09-21-1999	
	12	5,972,353		Zavada et al.	10-26-1999	
	13	5,981,711		Zavada et al.	11-09-1999	
✓	14	5,989,838		Zavada et al.	11-23-1999	
✓	15	6,004,535		Zavada et al.	12-21-1999	
Amu	16	6,027,887		Zavada et al.	02-22-2000	
	17	6,051,226		Zavada et al.	04-18-2000	
	18	6,069,242		Zavada et al.	05-30-2000	
	19	6,093,548		Zavada et al.	07-25-2000	
	20	6,204,370	B1	Zavada et al.	03-20-2001	
	21	6,297,041	B1	Zavada et al.	10-02-2001	
✓	22	6,297,051	B1	Zavada et al.	10-02-2001	
✓	23	6,770,438	B2	Zavada et al.	08-03-2004	
	24	6,774,117	B1	Zavada et al.	08-10-2004	

Examiner Signature	amuharris	Date Considered	11/20/2007
--------------------	-----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	Application Number	10/511,465
	Filing Date	October 14, 2004
	First Named Inventor	Matthew H.T. Bui
	Group Art Unit	Unassigned (643)
	Examiner Name	Unassigned A. M. Harris
	Attorney Docket Number	306J-000220US
	Date Submitted	March 29, 2005

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number				
amh	25	WO	93/18152	A1	CIBA Corning Diagnostics Corp.	09-16-1993	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
amh	26	BRETHEAU ET AL. (1995) "Prognostic value of nuclear grade of renal cell carcinoma." <i>Cancer</i> (Phila.) 76(12): 2543-2549.	
	27	BREWER ET AL. (1996) "A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN," <i>Gynecologic Oncology</i> 63: 337-344. (Article No. 0333)	
	28	BUI ET AL. (2001) "Prognostic factors and molecular markers for renal cell carcinoma." <i>Expert Review of Anticancer Therapy</i> , 1(4): 565-575.	
	29	BUI ET AL. (2003) "Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: Implications for Prognosis and Therapy." <i>Clinical Cancer Research</i> , 9:802-811.	
	30	DALBADIE-MCFARLAND ET AL. (1982) "Oligonucleotide-Directed Mutagenesis as a General and Powerful Method for Studies of Protein Function" <i>Proceeding of the National Academy of Sciences USA</i> , 79: 6409-6413.	
	31	DER AND STANBRIDGE (1981) "A tumor-specific membrane phosphoprotein marker in human cell hybrids." <i>Cell</i> 26: 429-438.	
	32	DIVGI ET AL. (1998) "Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma," <i>Clinical Cancer Research</i> , 4: 2729-2739.	
	33	ELSON ET AL. (1988) "Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma." <i>Cancer Research</i> , 48: 7310-7313.	
	34	FIGLIN (1999) "Renal cell carcinoma: management of advanced disease." <i>The Journal of Urology</i> , 161:381-386.	
	35	FLANIGAN ET AL. (2001) "Nephrectomy followed by interferon $\alpha$ -2b compared with interferon $\alpha$ -2b alone for metastatic renal-cell cancer." <i>New England Journal of Medicine</i> , 345(23): 1655-1659.	
✓	36	FUHRMAN ET AL. (1982) "Prognostic significance of morphologic parameters in renal cell carcinoma." <i>The American Journal of Surgical Pathology</i> , 6(7): 655-663.	

Examiner Signature	Amh Harris	Date Considered	11/20/2007
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Amu

37

GALFRE AND MILSTEIN (1981) "Preparation of Monoclonal Antibodies: Strategies and Procedures." *Methods in Enzymology*, 73: 1-46.

38

GIATROMANOLAKI ET AL. (2001) "Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer." *Cancer Research*, 61:7992-7998.

39

GLENNIE AND STEVENSON (1982) "Univalent antibodies kill tumour cells *in vitro* and *in vivo*." *Nature* 295: 712-714.

40

GORMAN ET AL. (1991) "Reshaping a Therapeutic CD4 Antibody." *Proceeding of the National Academy of Sciences USA*, 88:4181-4185.

41

IVANOV ET AL. (1998) "Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes," *Proceeding of the National Academy of Sciences USA*, 95:12596-12601.

42

IVANOV ET AL. (2001) "Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer." *American Journal of Pathology*, 158(3):905-919.

43

JEMAL ET AL. (2002) "Cancer Statistics, 2002" *CA-Cancer J. Clin.*, 52(1):23-47.

44

KAPLAN AND MEIER (1958) "Nonparametric estimation from incomplete observations." *American Statistical Association Journal*, 53: 457-481.

45

KONONEN ET AL. (1998) "Tissue microarrays for high-throughput molecular profiling of tumor specimens." *Nature Medicine*, 4(7): 844-847.

46

LIAO ET AL. (1994) "Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas." *American Journal of Pathology*, 145(3): 598-609.

47

LIAO ET AL. (1997) "Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney." *Cancer Research*, 57: 2827-2831.

48

LONCASTER ET AL. (2001) "Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix." *Cancer Research*, 61:6394-6399.

49

KOHLER AND MILSTEIN (1975) "Continuous cultures of fused cells secreting antibody of predefined specificity." *Nature* 256: 495-497.

50

MOTZER ET AL. (1999) "Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma." *Journal of Clinical Oncology*, 17(8): 2530-2540.

51

MURAKAMI ET AL. (1999) "MN/CA9 gene expression as a potential biomarker in renal cell carcinoma." *BJU International*, 83: 743-747.

52

OLIVE ET AL. (2001) "Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer," *Cancer Research*, 61:8924-8929.Examiner  
Signature*Matthew Harris*Date  
Considered

11/20/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

MAR 31 2005 CTO  
U.S. PATENT & TRADEMARK OFFICE

Application Number	10/511,465
Filing Date	October 14, 2004
First Named Inventor	Matthew H.T. Bui
Group Art Unit	Unassigned 1643
Examiner Name	Unassigned A.M. Harris
Attorney Docket Number	306J-000220US
Date Submitted	March 29, 2005

53	OLSSON AND KAPLAN (1980) "Human-Hunam hybridomas producing monoclonal antibodies of predefined antigenic specificity." <i>Proceeding of the National Academy of Sciences USA</i> , 77(9): 5429-5431.
54	OOSTERWIJK ET AL. (1986) "Immunohistochemical analysis of monoclonal antibodies to renal antigens." <i>American Journal of Pathology</i> 123(2):301-309
55	OOSTERWIJK ET AL. (1986) "Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney." <i>International Journal of Cancer</i> , 38: 489-494.
56	OOSTERWIJK ET AL. (1996) "Molecular characterization of the renal cell carcinomaassociated antigen G250," <i>Proceedings of the National Association for Cancer Research</i> , 37: #3147.
57	PANTUCK ET AL. (2001) "The changing natural history of renal cell carcinoma." <i>The Journal of Urology</i> , 166:1611-1623.
58	PARKKILA ET AL. (2000) "Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro." <i>Proceeding of the National Academy of Sciences USA</i> , 97(5):2220-2224.
59	PASTOREK ET AL. (1994) "Cloning and characterization of MN, a human tumor associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment." <i>Oncogene</i> 9: 2877-2888.
60	PASTOREKOVÁ ET AL. (1992) "A Novel Quasi-viral Agent, MaTu, Is a Two-Component system." <i>VIROLOGY</i> 187 :620-626.
61	RAK ET AL. (2002) "What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?" <i>Cancer Research</i> , 62:1931-1934.
62	ROILA ET AL. (1991) "Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales." <i>Annals of Oncology</i> 2: 437-439.
63	SAARNIO ET AL. (1998) "Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase. MN/CA IX, with potential value as a marker of cell proliferation." <i>Amreican Journal of Pathology</i> , 153(1):279-285.
64	SCHLOM ET AL. (1980) "Generation of human monoclonal antibodies reactive with human mammary carcinoma cells." <i>Proceeding of the National Academy of Sciences USA</i> , 77(11):6841-6845.
65	SHEARMAN ET AL. (1991) "Construction, expression, and biologic activity of murine/human chimeric antibodies with specificity for the human alpha/beta T cell receptor." <i>The Journal of Immunology</i> , 146(3): 928-935.
66	SHI ET AL. (1999) "Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic." <i>Clinical Cancer Research</i> , 5:3711-3721.

Examiner Signature	Anh Harris	Date Considered	11/20/2007
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/511,465
		Filing Date	October 14, 2004
		First Named Inventor	Matthew H.T. Bul
		Group Art Unit	Unassigned 1643
		Examiner Name	Unassigned A. M. Harris
		Attorney Docket Number	306J-000220US
		Date Submitted	March 29, 2005

SEARCHED & INDEXED APR 3 1 2005 JC10 E Am	67	SLAMON ET AL. (2001) "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2." <i>The New England Journal of Medicine</i> , 344(11):783-792.	
	68	SOBIN AND FLEMING (1997) "TNM Classification of Malignant Tumors, 5 Ed.." <u>Union Internationale Contre le Cancer and the American Joint Committee on Cancer</u> , <i>Cancer</i> (Phila.) 80: 1803-1804.	
	69	STEFFENS ET AL. (1997) "Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250," <i>Journal of Clinical Oncology</i> , 15(4): 1529-1537.	
	70	STEFFENS ET AL. (1999) "Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250." <i>Anticancer Research</i> , 19: 1197-1200.	
	71	STEFFENS ET AL. (1999) "Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250." <i>Clinical Cancer Research</i> , 5: 3268s-3274s.	
	72	STÖRKEL ET AL. (1997) "Classification of renal cell carcinoma: Workgroup No. 1." <u>Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)</u> , <i>Cancer</i> , 80(5): 987-989.	
	73	TSO ET AL. (2001) "Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor." <i>Cancer Research</i> , 61:7925-7933.	
	74	TURNER ET AL. (1997) "MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker." <i>Human Pathology</i> , 28: 740-744.	
	75	UEMURA ET AL. (1994) "Vaccination with anti-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity." <i>International Journal of Cancer</i> , 58: 555-561.	
	76	UEMURA ET AL. (1997) "Expression of tumor-associated antigen MN/G250 in urologic carcinoma: potential therapeutic target." <i>The Journal of Urology</i> , 157(4)(Suppl): #1475.	
	77	UEMURA ET AL. (1999) "MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas." <i>British Journal of Cancer</i> , 81(4):741-746.	
	78	VAN DIJK ET AL. (1989) "Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen." <i>International Journal of Cancer</i> , 43: 344-349.	
	79	VISSERS ET AL. (1999) "The renal cell carcinoma associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes." <i>Cancer Research</i> , 59: 5554-5559.	

Examiner Signature	Am Harris	Date Considered	11/28/2007
--------------------	-----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/511,465
		Filing Date	October 14, 2004
		First Named Inventor	Matthew H.T. Bui
		Group Art Unit	Unassigned 1643
		Examiner Name	Unassigned A.M. Harris
		Attorney Docket Number	306J-000220US
		Date Submitted	March 29, 2005

<i>P E</i> <i>MAR 3 1 2005</i> <i>ST. PETERSBURG</i>	80	WYKOFF ET AL. (2000) "Hypoxia-inducible expression of tumor-associated carbonic anhydrases." <i>Cancer Research</i> , 60:7075-7083.	
	81	WYKOFF ET AL. (2000) "Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling." <i>Oncogene</i> , 19: 6297-6305.	
	82	ZAVADA ET AL. (1993) "Expression of MaTu-MN protein in human tumor cultures and in clinical specimens." <i>International Journal of Cancer</i> , 54: 268-274.	
<i>V</i>	83	ZISMAN ET AL. (2001) "Improved prognostication of renal cell carcinoma using an integrated staging system." <i>Journal of Clinical Oncology</i> , 19(6):1649-1657.	

Examiner Signature	<i>A.M. Harris</i>	Date Considered	11/20/2007
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.